Cirrus Pharmaceuticals to Invest in cGMP Manufacturing Suite in US
News Nov 13, 2014
Cirrus Pharmaceuticals has announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina.
Ninad Deshpanday, President of R&D at Kemwell said, “With this investment, we are bringing our customers a new service from our US facility. We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. Our clients will be able to use this service to go to clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”
Today, Kemwell’s R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing.
The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world, including virtual, small and big pharma.
With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018